1P-ETH-LAD

1P-ETH-LAD

1P-ETH-LAD, also known as 1-propionyl-ETH-LAD or 1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide, is an N1-acyl derivative of ETH-LAD. It combines the N6-ethyl substitution of ETH-LAD with a propionyl group attached to the indole nitrogen. It is therefore related to both ETH-LAD and 1P-LSD, but differs from each at a specific position of the lysergamide structure.

Structure and analytical characterization

In LSD, the N6 position carries a methyl group. ETH-LAD has an ethyl group at that position, while 1P-ETH-LAD retains the ethyl substituent and adds a propionyl group at N1. This is different from 1P-LSD, which carries the same N1-propionyl group but retains LSD’s N6-methyl group.

The distinction also explains why 1P-ETH-LAD is a constitutional isomer of 1B-LSD. In 1B-LSD, the N1 group is butanoyl and N6 remains methyl. In 1P-ETH-LAD, the N1 group is propionyl and N6 is ethyl. Brandt and colleagues characterized both compounds in separate studies, using mass spectrometry, chromatography and NMR to distinguish their structures.

Brandt and colleagues included an incubation experiment in their 2017 analytical study of ETH-LAD and 1P-ETH-LAD. When 1P-ETH-LAD was incubated with human serum at 37°C, ETH-LAD was already detectable at the first sampling point, one hour after incubation began. The parent compound was still present after 24 hours. This supports a possible conversion to ETH-LAD, but does not show how the process unfolds in a living person.

Metabolism and pharmacological evidence

There is no comparable controlled human pharmacokinetic study for 1P-ETH-LAD, and no direct receptor study has established its activity at 5-HT2A. A prodrug role is plausible, although it may not fully explain the compound’s pharmacology. It remains possible that the intact compound has activity of its own or that the time course of conversion differs between an in-vitro serum preparation and the human body.

Reported effects

The descriptions gathered in PsychonautWiki’s 1P-ETH-LAD entry compare the experience with ETH-LAD and AL-LAD, but emphasize its visual and cognitive character. The accounts are anecdotal, and the entry itself notes that the effects section is incomplete.

Physical and visual effectsCognitive and emotional effects
  • Stimulation: increased energy and a fast-moving physical experience are described.
  • Bodily sensations: tingling and tactile enhancement appear in user reports.
  • Visual changes: colour enhancement, drifting surfaces, tracers and geometric patterns are mentioned.
  • Synaesthetic impressions: some accounts describe unusual connections between sensory experiences.
  • Physical discomfort: nausea and bodily tension are also reported.
  • Analytical thinking: reports describe introspection and a more detached or analytical headspace.
  • Thought acceleration: ideas may move quickly, sometimes developing into thought loops.
  • Music appreciation: music may seem unusually engaging or detailed.
  • Anxiety: some reports describe anxiety or unease, despite other accounts portraying the experience as emotionally manageable.

Some users describe the experience as less emotionally charged than LSD, while others report discomfort or anxiety. Since conversion to ETH-LAD has only been examined in vitro, the available evidence cannot show whether the reported effects are produced by 1P-ETH-LAD itself, ETH-LAD formed after exposure or both.

1P-ETH-LAD Products

1P-ETH-LAD pellets

1P-ETH-LAD pellets

Price range: $473.00 through $2,930.00
Select options
1P-ETH-LAD liquid

1P-ETH-LAD liquid

Price range: $410.00 through $2,882.00
Select options
1P-ETH-LAD blotters

1P-ETH-LAD blotters

Price range: $420.00 through $2,100.00
Select options

Scientific Data

Identity and Structure

Chemical Name1P-ETH-LAD
Catalog Entity TypeCompound
FormulaC24H31N3O2
Molar Mass393.531 g·mol−1
CAS2230715-45-2
CAS Numbers and Substance Forms2230715-45-2
Synonyms1-Propionyl-ETH-LAD; 1-Propionyl-6-ethyl-6-nor-LSD
IUPAC Name(6aR,9R)-N,N-Diethyl-7-ethyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
InChIInChI=1S/C24H31N3O2/c1-5-22(28)27-15-16-13-21-19(18-10-9-11-20(27)23(16)18)12-17(14-26(21)8-4)24(29)25(6-2)7-3/h9-12,15,17,21H,5-8,13-14H2,1-4H3/t17-,21-/m1/s1
InChIKeyMLOFCBXSOAYCIF-DYESRHJHSA-N
SMILESCCC(=O)N1C=C2C[C@@H]3C(=C[C@H](CN3CC)C(=O)N(CC)CC)C4=C2C1=CC=C4

Chemical Identifiers

PubChem CID119025859
ChemSpider ID52085137
UNIIHA76076A0R
CompTox DTXSIDDTXSID301016300

Clinical Data

Drug ClassSerotonergic psychedelic; Hallucinogen
Routes of AdministrationOral

Legal Status

Legal Status (Wikipedia Source Text)DE: NpSG (Industrial and scientific use only)
UK: Under Psychoactive Substances Act
Illegal in France

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=56708836